SCHEMBL22718290

SCHEMBL22718290

COc1ccc(CN(C)S(=O)(=O)c2ccc(Nc3ccc(C(F)(F)F)cn3)c(-c3cn(Cc4ccccc4F)cn3)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR6 P51684 1/20 0.37
▸ MAOA P21397 2/20 0.36
▸ CASP3 P42574 2/20 0.36
▸ MMP1 P03956 2/20 0.36
▸ MMP9 P14780 2/20 0.36
▸ MMP13 P45452 2/20 0.36
▸ TEAD1 P28347 1/20 0.36
▸ YAP1 P46937 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ MDM2 Q00987 1/20 0.35
▸ BMP1 P13497 1/20 0.35
▸ TRPV1 Q8NER1 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ LIPE Q05469 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29438945 1.00 CCR6 (0.37) CCR6MAOACASP3MMP1MMP9
SCHEMBL22718153 0.92 MMP1 (0.40) CCR6MMP1MMP9MMP13TEAD1
SCHEMBL22843429 0.88 TEAD1 (0.39) CCR6MAOACASP3TEAD1YAP1
SCHEMBL24496050 0.87 TEAD1 (0.39) CCR6MMP1MMP9MMP13TEAD1
SCHEMBL24496141 0.87 CCR6 (0.39) CCR6MAOAMMP1MMP9MMP13
SCHEMBL22718251 0.86 TEAD1 (0.49) CCR6MAOACASP3MMP1MMP9
SCHEMBL29438917 0.86 TEAD1 (0.49) CCR6MAOACASP3MMP1MMP9
SCHEMBL29438915 0.86 TEAD1 (0.49) CCR6MAOACASP3MMP1MMP9
SCHEMBL22718139 0.84 CCR6 (0.40) CCR6MAOACASP3MMP1MMP9
SCHEMBL22718255 0.83 MMP1 (0.40) CCR6MMP1MMP9MMP13KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 — — US disclosed
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2024-03-14 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2022-08-11 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CCR6 4335/4885MAOA 1322/4885CASP3 1825/4885
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 CCR6 4335/4885MAOA 1322/4885CASP3 1825/4885
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CCR6 4335/4885MAOA 1322/4885CASP3 1825/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 CCR6 4335/4885MAOA 1322/4885CASP3 1825/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 CCR6 2313/4885MAOA 2235/4885CASP3 2289/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CCR6 4335/4885MAOA 1322/4885CASP3 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback